Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jan 26;12(2):251.
doi: 10.3390/antibiotics12020251.

Comparison between EUCAST Broth Microdilution and MIC Strip Test in Defining Isavuconazole In Vitro Susceptibility against Candida and Rare Yeast Clinical Isolates

Maddalena Calvo  1 , Guido Scalia  1   2 , Concetta Ilenia Palermo  1 , Salvatore Oliveri  2 , Laura Trovato  1   2
Affiliations

Comparison between EUCAST Broth Microdilution and MIC Strip Test in Defining Isavuconazole In Vitro Susceptibility against Candida and Rare Yeast Clinical Isolates

Maddalena Calvo et al. Antibiotics (Basel). .

Abstract

Isavuconazole is a new broad-spectrum triazole, with significant in vitro activity against yeasts. Isavuconazole in vitro susceptibility can be evaluated through broth microdilution as a reference method. Considering difficulties in equipping such methods in a laboratory routine, a commercial MIC Strip test has been designed. This study aims to implement data about isavuconazole in vitro activity and compare EUCAST broth microdilution and MIC Strip test in defining yeast isavuconazole susceptibility. The study involved 629 isolates from positive blood cultures (January 2017-December 2021). The identified species were C. albicans (283), C. glabrata (53), C. krusei (23), C. tropicalis (68), C. parapsilosis complex (151), C. guilliermondii (12), C. famata (6), S. cerevisiae (12), C. neoformans (5), S. capitata (12), and Rhodotorula species (4). All the isolates were tested with EUCAST microdilution and MIC Strip methods. The total essential agreement between these two methods was 99.3%. As a result, we can consider that both methods are useful in testing isavuconazole susceptibility. Proposed cut-off values (P-ECOFF) were calculated using ECOFFinder software. Further studies could lead to either definitive E-COFF or clinical breakpoints, which represent the most important categorization tool of the laboratory data, allowing a better insertion of an antimicrobial drug in clinical practice.

Keywords: EUCAST; antifungal susceptibility; isavuconazole; yeasts.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Isolates distribution among hospital wards.
Figure 2
Figure 2
Essential agreement between the EUCAST reference method and MIC strips.
See this image and copyright information in PMC

References

    1. European Medicines Agency (EMA) Cresemba: EPAR e Product Information. EMA; Amsterdam, The Netherlands: 2015.
    1. Denis J., Ledoux M.P., Nivoix Y., Herbrecht R. Isavuconazole: A new broad-spectrum azole. Part 1: In vitro activity. J. Mycol. Med. 2018;3:8–14. doi: 10.1016/j.mycmed.2018.02.005. - DOI - PubMed
    1. Guinea J., Bouza E. Isavuconazole: A new and promising antifungal triazole for the treatment of invasive fungal infections. Future Microbiol. 2008;3:603–615. doi: 10.2217/17460913.3.6.603. - DOI - PubMed
    1. Girmenia C. New generation azole antifungals in clinical investigation. Expert Opin. Investig. Drugs. 2009;3:1279–1295. doi: 10.1517/13543780903176407. - DOI - PubMed
    1. Livermore J., Hope W. Evaluation of the pharmacokinetics and clinical utility of isavuconazole for treatment of invasive fungal infections. Expert Opin. Drug Metab. Toxicol. 2012;3:759–765. doi: 10.1517/17425255.2012.683859. - DOI - PubMed